Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 t-haNK in Relapsed B-cell Acute Lymphoblastic Leukemia
NCT07556757Phase 1Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Apr 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19t-haNK in acute lymphoblastic leukemia (ALL), sponsored by ImmunityBio, Inc. Primary endpoint: Adverse Events at 12 months. Started Apr 2025; status: terminated.
02
Drugs
CD19t-haNK
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07556757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556757.